Switch rates during acute treatment for Bipolar II depression with Lithium, Sertraline, or the two combined: A randomized double-blind comparison

American Journal of Psychiatry

Volumn 174, Issue 3, 2017, Pages 266-276

  Altshuler, Lori L ^a   Sugar, Catherine A ^a   McElroy, Susan L ^a   Calimlim, Brian ^a   Gitlin, Michael ^a   Keck, Paul E ^a   Aquino Elias, Ana ^a   Martens, Brian E ^a   Fischer, E Grace ^a   English, Teri L ^a   Roach, Janine ^a   Suppes, Trisha ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; SERTRALINE; LITHIUM CARBONATE;

ADULT; ARTICLE; BIPOLAR II DISORDER; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SUBSTITUTION; FEMALE; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOOD DISORDER ASSESSMENT; PATIENT DROPOUT; RANDOM SAMPLE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME; TREATMENT RESPONSE; AFFECT; BIPOLAR DISORDER; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RISK;

ADULT; AFFECT; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; MIDDLE AGED; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; RISK; SERTRALINE; TREATMENT OUTCOME;

EID: 85014493601     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2016.15040558     Document Type: Article

References (43)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: DSM-5. Washington, DC, American Psychiatric Association, 2013
2. Judd LL, Akiskal HS, Schettler PJ, et al: A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261-269
3. Kupka RW, Altshuler LL, Nolen WA, et al: Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 2007; 9: 531-535
4. Cassano GB, Dell'Osso L, Frank E, et al: The bipolar spectrum: A clinical reality in search of diagnostic criteria and an assessment methodology. J Affect Disord 1999; 54: 319-328
5. Rouillon F, Lejoyeux M, Filteau MJ: Unwanted effects of long-term treatment, in Long-Term Treatment of Depression. Edited by Montgomery SA, Rouillon FA. New York, John Wiley & Sons, 1992
6. Prien RF, Kupfer DJ, Mansky PA, et al: Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984; 41: 1096-1104
7. Viktorin A, Lichtenstein P, Thase ME, et al: The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry 2014; 171: 1067-1073
8. Ghaemi SN, Hsu DJ, Soldani F, et al: Antidepressants in bipolar disorder: The case for caution. Bipolar Disord 2003; 5: 421-433
9. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al: The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolardisorders. AmJPsychiatry 2013; 170: 1249-1262
10. American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder, 2nd edition. Am J Psychiatry 2002; 159(April suppl): 1-50
11. Sachs GS, Printz DJ, Kahn DA, et al: The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med 2000 (spec no): 1-104
12. Swartz HA, Thase ME: Pharmacotherapy for the treatment of acute bipolar II depression: Current evidence. J Clin Psychiatry 2011; 72: 356-366
13. Van Lieshout RJ, MacQueenGM: Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: Systematic review. Br J Psychiatry 2010; 196: 266-273
14. Vieta E, Locklear J, Günther O, et al: Treatment options for bipolar depression: A systematic review of randomized, controlled trials. J Clin Psychopharmacol 2010; 30: 579-590
15. Malhi GS, Mitchell PB, Salim S: Bipolar depression: Management options. CNS Drugs 2003; 17: 9-25
16. Suppes T, Dennehy EB: Evidence-based long-term treatment of bipolar II disorder. J Clin Psychiatry 2002; 63(suppl 10): 29-33
17. Baldessarini RJ, Leahy L, Arcona S, et al: Patterns of psychotropic drug prescription for US patients with diagnoses of bipolar disorders. Psychiatr Serv 2007; 58: 85-91
18. Joffe RT, MacQueen GM, Marriott M, et al: Induction of mania and cycle acceleration in bipolar disorder: Effect of different classes of antidepressant. Acta Psychiatr Scand 2002; 105: 427-430
19. Serretti A, Artioli P, Zanardi R, et al: Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 751-757
20. Altshuler LL, Suppes T, Black DO, et al: Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006; 163: 313-315
21. McElroy SL, Weisler RH, Chang W, et al: A double-blind, placebocontrolled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71: 163-174
22. Post RM, Denicoff KD, Leverich GS, et al: Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003; 64: 680-690
23. Altshuler LL, Gitlin MJ, Mintz J, et al: Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 2002; 63: 807-811
24. Vieta E, Benabarre A, ColomF, et al: Suicidalbehavior in bipolar Iand bipolar II disorder. J Nerv Ment Dis 1997; 185: 407-409
25. Rihmer Z, Pestality P: Bipolar II disorder and suicidal behavior. Psychiatr Clin North Am 1999; 22: 667-673
26. Stallone F, Dunner DL, Ahearn J, et al: Statistical predictions of suicide in depressives. Compr Psychiatry 1980; 21: 381-387
27. Dunner DL, Gershon ES, Goodwin FK: Heritable factors in the severity of affective illness. Biol Psychiatry 1976; 11: 31-42
28. MacQueen GM, Young LT: Bipolar II disorder: Symptoms, course, and response to treatment. Psychiatr Serv 2001; 52: 358-361
29. Spitzer RL, Williams JBW, Gibbon M, et al: Structured Clinical Interview for DSM-IV (SCID). New York, New York State Psychiatric Institute, Biometrics Research, 1996
30. Rush AJ, Gullion CM, Basco MR, et al: The Inventory of Depressive Symptomatology (IDS): Psychometric properties. PsycholMed1996; 26: 477-486
31. Spearing MK, Post RM, Leverich GS, et al: Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): The CGI-BP. Psychiatry Res 1997; 73: 159-171
32. Young RC, Biggs JT, Ziegler VE, et al: A rating scale for mania: Reliability, validity, and sensitivity. Br J Psychiatry 1978; 133: 429-435
33. Carvalho AF, Dimellis D, Gonda X, et al: Rapid cycling in bipolar disorder: A systematic review. J Clin Psychiatry 2014; 75: E578-e586
34. AmsterdamJD, Shults J: Efficacy andmoodconversion rate of shortterm fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol 2010; 30: 306-311
35. Amsterdam JD, Shults J, Brunswick DJ, et al: Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression: Low manic switch rate. Bipolar Disord 2004; 6: 75-81
36. Amsterdam JD, Wang CH, Shwarz M, et al: Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: A randomized, parallel group, open-label trial. J Affect Disord 2009; 112: 219-230
37. Amsterdam JD, Luo L, Shults J: Effectiveness and mood conversion rate of short-term fluoxetine monotherapy in patients with rapid cycling bipolar II depression versus patients with nonrapid cycling bipolar II depression. J Clin Psychopharmacol 2013; 33: 420-424
38. Ostacher MJ, Perlis RH, Nierenberg AA, et al: Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: Prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2010; 167: 289-297
39. Suppes T, Marangell LB, Bernstein IH, et al: A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008; 111: 334-343
40. Amsterdam JD, Shults J: Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: A double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol 2005; 20: 257-264
41. Ostacher MJ, Tandon R, Suppes T: Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Bipolar Disorder: A novel, practical, patient-centered guide for clinicians. J Clin Psychiatry 2016; 77: 920-926
42. Yatham LN, Kennedy SH, Parikh SV, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update ofCANMAT guidelines for the management of patients with bipolar disorder: Update 2013. Bipolar Disord 2013; 15: 1-44
43. Amsterdam JD, Shults J: Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: A randomized, double-blind, placebo-substitution study. Am J Psychiatry 2010; 167: 792-800